- Home
- MCD vs NVS Comparison
MCD vs NVS Comparison
Compare MCD & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCD | NVS |
|---|---|---|
| Founded | 1940 | 1895 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.6B | 266.5B |
| IPO Year | N/A | 1991 |
Fundamental Metrics
Financial Performance| Metric | MCD | NVS |
|---|---|---|
| Price | $305.18 | $144.99 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 26 | 5 |
| Target Price | ★ $328.79 | $118.00 |
| AVG Volume (30 Days) | ★ 3.0M | 1.4M |
| Earning Date | 02-09-2026 | 02-04-2026 |
| Dividend Yield | ★ 2.46% | 1.81% |
| EPS Growth | ★ 2.90 | N/A |
| EPS | ★ 11.72 | 7.30 |
| Revenue | $26,264,000,000.00 | ★ $56,372,000,000.00 |
| Revenue This Year | $3.94 | $9.38 |
| Revenue Next Year | $5.65 | $2.69 |
| P/E Ratio | $25.84 | ★ $19.67 |
| Revenue Growth | 1.25 | ★ 12.88 |
| 52 Week Low | $278.73 | $97.72 |
| 52 Week High | $326.32 | $146.35 |
Technical Indicators
Market Signals| Indicator | MCD | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 45.19 | 66.48 |
| Support Level | $302.45 | $142.82 |
| Resistance Level | $311.18 | $146.35 |
| Average True Range (ATR) | 4.23 | 2.12 |
| MACD | -0.26 | 0.09 |
| Stochastic Oscillator | 50.97 | 86.39 |
Price Performance
Historical ComparisonAbout MCD McDonald's Corporation
McDonald's is the world's largest restaurant brand, with nearly $131 billion in systemwide sales across more than 44,000 restaurants and over 100 markets. The quick-service chain built its early reputation on speed, consistency, and affordable hamburgers, and today its global menu spans burgers, chicken, breakfast, and beverages that have helped popularize American fast-food cuisine worldwide. The firm derives the bulk of its revenue from franchise royalties and rent (about 61%), with the remainder stemming from company-operated restaurants across three segments: the United States (41% of systemwide sales), international operated markets (34%), and international developmental/licensed markets (25%).
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.